Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02209701
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: 131I-Sibrotuzumab
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT02209727
Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIIF 1149 BSDrug: Placebo
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02209714
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: ESR 1150 CL
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT02209688
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02209844
Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT02209831
Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIRB 796 BS, low doseDrug: BIRB 796 BS, high doseDrug: Placebo
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02209805
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: BIRB 796 BS, low doseDrug: BIRB 796 BS, medium dose 1Drug: BIRB 796 BS, medium dose 2Drug: BIRB 796 BS, high doseDrug: Placebo
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 182
- Registration Number
- NCT02209753
Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02209649
Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: PlaceboDrug: BIBR 796 BS
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 167
- Registration Number
- NCT02209779